MONDAY, Oct. 14, 2024 (HealthDay News) -- As with any new drug, parents and doctors may worry that the use of GLP-1 ...

A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...

However, GLP-1-based therapies aren't going to be the only option in the weight loss medicines market forever. Some companies ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

Met With High Demand, the Dual-Product System is Clinically Shown to Increase GLP-1 by 140% on average to Balance Hunger ...

While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.

Supergut, the only nutrition brand clinically-validated to improve digestive health and curb cravings, is rolling out ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

WeightWatchers said it will sell compounded versions of semaglutide — the key ingredient in Novo Nordisk's Ozempic and Wegovy ...